At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 510 enrolled
Drug / intervention
pazopanib eye drops +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
In Brief
A Phase 2 clinical trial evaluating pazopanib eye drops, placebo, and 1 other intervention for Macular Degeneration. Completed, enrolled 510 participants across 77 sites in 9 countries.
Detailed Summary
The purpose of this study is to determine the safety and efficacy of different dosage regimens of pazopanib eye drops for the treatment of neovascular age-related macular degeneration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Degeneration
CountriesAustralia, Belgium, Canada, Denmark, Germany, Italy, Japan, Sweden, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2010
Enrollment StartJun 2010
Primary CompletionOct 2012
TodayJul 2026
First PostedMay 31, 2010
Enrollment StartJun 1, 2010
Primary CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 16.1 years ago
Interventions
pazopanib eye dropsdrug
A tyrosine kinase inhibitor of multiple receptors including vascular endothelial growth factor receptors and platelet-derived growth factor receptors.
placebodrug
placebo eye drops
ranibizumab intravitreal injectionbiological
Humanized recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A